Multiple Sclerosis in Children

ABSTRACT

Multiple sclerosis (MS) is being increasingly diagnosed in children and adolescents. Clinical and magnetic resonance imaging (MRI) features of MS in the pediatric population are similar to adult-onset disease, with some important distinctions. Case vignettes, recently published clinical definitions, and an approach to disorders considered in the differential diagnoses are provided in this article. Immunomodulatory therapies approved for use in adults with MS are safe and well-tolerated in children, although monitoring of liver function is of particular importance. Finally, this article presents recent research studies performed in an MS population for whom disease onset occurs in unique temporal proximity to the events involved in MS pathogenesis.

KEYWORDS

Multiple sclerosis - children - demyelination

REFERENCES

• 1 Boiko A, Vorobeychik G, Paty D et al.. Early onset multiple sclerosis: a longitudinal study.  Neurology. 2002;  59(7) 1006-1010
• 2 Duquette P, Murray T J, Pleines J et al.. Multiple sclerosis in childhood: clinical profile in 125 patients.  J Pediatr. 1987;  111(3) 359-363
• 3 Simone I L, Carrara D, Tortorella C et al.. Course and prognosis in early-onset MS: comparison with adult-onset forms.  Neurology. 2002;  59(12) 1922-1928
• 4 Ruggieri M, Polizzi A, Pavone L, Grimaldi L M. Multiple sclerosis in children under 6 years of age.  Neurology. 1999;  53(3) 478-484
• 5 Ghezzi A, Pozzilli C, Liguori M et al.. Prospective study of multiple sclerosis with early onset.  Mult Scler. 2002;  8(2) 115-118
• 6 Mikaeloff Y, Caridade G, Assi S, Suissa S, Tardieu M. Prognostic factors for early severity in a childhood multiple sclerosis cohort.  Pediatrics. 2006;  118(3) 1133-1139
• 7 Dessa Sadovnick A. The genetics of multiple sclerosis.  Clin Neurol Neurosurg. 2002;  104 199-202
• 8 Wingerchuk D M, Weinshenker B G. Neuromyelitis optica.  Curr Treat Options Neurol. 2005;  7(3) 173-182
• 9 Wingerchuk D M, Lennon V A, Pittock S J, Lucchinetti C F, Weinshenker B G. Revised diagnostic criteria for neuromyelitis optica.  Neurology. 2006;  66(10) 1485-1489
• 10 Krupp L B, Banwell B, Tenembaum S. International Pediatric MS Study Group . Consensus definitions proposed for pediatric multiple sclerosis.  Neurology. 2007;  68 S7-S12
• 11 Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients.  Neurology. 2002;  59(8) 1224-1231
• 12 Rust R S. Multiple sclerosis, acute disseminated encephalomyelitis, and related conditions.  Semin Pediatr Neurol. 2000;  7(2) 66-90
• 13 Wilejto M, Shroff M, Buncic J R, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children.  Neurology. 2006;  67(2) 258-262
• 14 Riikonen R, Donner M, Erkkila H. Optic neuritis in children and its relationship to multiple sclerosis: a clinical study of 21 children.  Dev Med Child Neurol. 1988;  30(3) 349-359
• 15 Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis.  Neurology. 2004;  63(10) 1966-1967
• 16 McDonald W I, Compston A, Edan G et al.. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.  Ann Neurol. 2001;  50(1) 121-127
• 17 Hahn C D, Miles B S, MacGregor D L, Blaser S I, Banwell B L, Hetherington C R. Neurocognitive outcome after acute disseminated encephalomyelitis.  Pediatr Neurol. 2003;  29(2) 117-123
• 18 Mikaeloff Y, Adamsbaum C, Husson B et al.. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood.  Brain. 2004;  127(Pt 9) 1942-1947
• 19 Banwell B, Shroff M, Ness J et al.. MRI features of pediatric multiple sclerosis.  Neurology. 2007;  68 S46-S53
• 20 Shiraishi K, Higuchi Y, Ozawa K, Hao Q, Saida T. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan.  Brain Dev. 2005;  27(3) 224-227
• 21 Ozakbas S, Idiman E, Baklan B, Yulug B. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features.  Brain Dev. 2003;  25(4) 233-236
• 22 Mikaeloff Y, Suissa S, Vallee L et al.. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability.  J Pediatr. 2004;  144(2) 246-252
• 23 Mikaeloff Y, Caridade G, Huson B, Suissa S, Tardieu M. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse.  Eur J Paediatr Neurol. 2007;  11(2) 90-95
• 24 Banwell B L. Pediatric multiple sclerosis.  Curr Neurol Neurosci Rep. 2004;  4(3) 245-252
• 25 Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features.  Acta Neurol Scand. 1992;  86(3) 280-284
• 26 Banwell B L, Anderson P E. The cognitive burden of multiple sclerosis in children.  Neurology. 2005;  64(5) 891-894
• 27 MacAllister W S, Belman A L, Milazzo M et al.. Cognitive functioning in children and adolescents with multiple sclerosis.  Neurology. 2005;  64(8) 1422-1425
• 28 Kalb R C, DiLorenzo T A, LaRocca N A, Caruso L S, Shawaryn M A, Elkin R DWM. The impact of early onset multiple sclerosis on cognitive and social indices.  Int J MS Care. 1999;  1 2-17
• 29 Mikaeloff Y, Moreau T, Debouverie M et al.. Interferon-beta treatment in patients with childhood-onset multiple sclerosis.  J Pediatr. 2001;  139(3) 443-446
• 30 Banwell B. Treatment of children and adolescents with multiple sclerosis.  Expert Rev Neurother. 2005;  5(3) 391-401
• 31 Zelnik N, Gale A D, Shelburne Jr S A. Multiple sclerosis in black children.  J Child Neurol. 1991;  6(1) 53-57
• 32 Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies.  J Rheumatol. 2006;  33(9) 1873-1877
• 33 Sibbitt Jr W L, Brandt J R, Johnson C R et al.. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus.  J Rheumatol. 2002;  29(7) 1536-1542
• 34 Yu H H, Lee J H, Wang L C, Yang Y H, Chiang B L. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study.  Lupus. 2006;  15(10) 651-657
• 35 Benseler S M, Silverman E, Aviv R I et al.. Primary central nervous system vasculitis in children.  Arthritis Rheum. 2006;  54(4) 1291-1297
• 36 Benseler S, Schneider R. Central nervous system vasculitis in children.  Curr Opin Rheumatol. 2004;  16(1) 43-50
• 37 Murphy J M, Gomez-Anson B, Gillard J H et al.. Wegener granulomatosis: MR imaging findings in brain and meninges.  Radiology. 1999;  213(3) 794-799
• 38 Krause I, Uziel Y, Guedj D et al.. Childhood Behçet's disease: clinical features and comparison with adult-onset disease.  Rheumatology (Oxford). 1999;  38(5) 457-462
• 39 Read R W, Holland G N, Rao N A et al.. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.  Am J Ophthalmol. 2001;  131(5) 647-652
• 40 Susac J O, Murtagh F R, Egan R A et al.. MRI findings in Susac's syndrome.  Neurology. 2003;  61(12) 1783-1787
• 41 Lamy C, Oppenheim C, Meder J F, Mas J L. Neuroimaging in posterior reversible encephalopathy syndrome.  J Neuroimaging. 2004;  14(2) 89-96
• 42 Kumar R, Singh S N, Kohli N. A diagnostic rule for tuberculous meningitis.  Arch Dis Child. 1999;  81(3) 221-224
• 43 Garcia H H, Del Brutto O H. Neurocysticercosis: updated concepts about an old disease.  Lancet Neurol. 2005;  4(10) 653-661
• 44 Singhi P, Ray M, Singhi S, Khandelwal N. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy.  J Child Neurol. 2000;  15(4) 207-213
• 45 Morgado C, Ruivo N. Imaging meningo-encephalic tuberculosis.  Eur J Radiol. 2005;  55(2) 188-192
• 46 Shaw C M, Alvord Jr E C. Multiple sclerosis beginning in infancy.  J Child Neurol. 1987;  2(4) 252-256
• 47 Iannetti P, Falconieri P, Imperato C. Acquired immune deficiency syndrome in childhood. Neurological aspects.  Childs Nerv Syst. 1989;  5(5) 281-287
• 48 Offiah C E, Turnbull I W. The imaging appearances of intracranial CNS infections in adult HIV and AIDS patients.  Clin Radiol. 2006;  61(5) 393-401
• 49 Garcia-Suarez J, de Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.  Am J Hematol. 2005;  80(4) 271-281
• 50 Lewis D W. Toward the definition of childhood migraine.  Curr Opin Pediatr. 2004;  16(6) 628-636
• 51 Swartz R H, Kern R Z. Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis.  Arch Neurol. 2004;  61(9) 1366-1368
• 52 Desmond D W, Moroney J T, Lynch T, Chan S, Chin S S, Mohr J P. The natural history of CADASIL: a pooled analysis of previously published cases.  Stroke. 1999;  30(6) 1230-1233
• 53 Valanne L, Ketonen L, Majander A, Suomalainen A, Pihko H. Neuroradiologic findings in children with mitochondrial disorders.  AJNR Am J Neuroradiol. 1998;  19(2) 369-377
• 54 Moore D F, Kaneski C R, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease.  J Neurol Sci. 2007;  257 258-263
• 55 Ries M, Ramaswami U, Parini R et al.. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.  Eur J Pediatr. 2003;  162(11) 767-772
• 56 van der Knaap M S. Magnetic resonance in childhood white-matter disorders.  Dev Med Child Neurol. 2001;  43(10) 705-712
• 57 Horster F, Surtees R, Hoffmann G F. Disorders of intermediary metabolism: toxic leukoencephalopathies.  J Inherit Metab Dis. 2005;  28(3) 345-356
• 58 Barkovich J A. Pediatric Neuroimaging. 2nd ed. New York; Raven Press 2000
• 59 Porto L, Kieslich M, Schwabe D, Yan B, Zanella F E, Lanfermann H. Central nervous system lymphoma in children.  Pediatr Hematol Oncol. 2005;  22(3) 235-246
• 60 Haddad E, Sulis M L, Jabado N, Blanche S, Fischer A, Tardieu M. Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis.  Blood. 1997;  89(3) 794-800
• 61 Pande A R, Ando K, Ishikura R et al.. Disseminated necrotizing leukoencephalopathy following chemoradiation therapy for acute lymphoblastic leukemia.  Radiat Med. 2006;  24(7) 515-519
• 62 Chan Y L, Leung S F, King A D, Choi P H, Metreweli C. Late radiation injury to the temporal lobes: morphologic evaluation at MR imaging.  Radiology. 1999;  213(3) 800-807
• 63 Boyd J R, MacMillan L J. Multiple sclerosis in childhood: understanding and caring for children with an “adult” disease.  Axone. 2000;  22(2) 15-21
• 64 Hahn J S, Siegler D J, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis.  Neurology. 1996;  46(4) 1173-1174
• 65 Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis.  Pediatr Neurol. 1999;  21(2) 583-586
• 66 Murthy S N, Faden H S, Cohen M E, Bakshi R. Acute disseminated encephalomyelitis in children.  Pediatrics. 2002;  110(2 Pt 1) e21
• 67 Apak R A, Anlar B, Saatci I. A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment.  Brain Dev. 1999;  21(4) 279-282
• 68 Weinshenker B G, O'Brien P C, Petterson T M et al.. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.  Ann Neurol. 1999;  46(6) 878-886
• 69 The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology. 1993;  43(4) 655-661
• 70 PRISMS . Randomised Double-Blind Placebo-Controlled Study of Interferon beta-1a in Relapsing-Remitting MS.  Lancet. 1998;  352 1498-1504
• 71 Jacobs L D, Cookfair D L, Rudick R A et al.. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [see comments] [published erratum appears in Ann Neurol 1996;40(3):480].  Ann Neurol. 1996;  39(3) 285-294
• 72 Johnson K P, Brooks B R, Cohen J A et al.. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial.  The Copolymer 1 Multiple Sclerosis Study Group . Neurology. 1995;  45(7) 1268-1276
• 73 Jacobs L D, Beck R W, Simon J H et al.. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.  CHAMPS Study Group . N Engl J Med. 2000;  343(13) 898-904
• 74 Comi G, Filippi M, Barkhof F et al.. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet. 2001;  357(9268) 1576-1582
• 75 Kappos L, Traboulsee A, Constantinescu C et al.. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.  Neurology. 2006;  67(6) 944-953
• 76 Banwell B, Reder A T, Krupp L et al.. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.  Neurology. 2006;  66(4) 472-476
• 77 Waubant E, Hietpas J, Stewart T et al.. Interferon beta-1a in children with multiple sclerosis is well tolerated.  Neuropediatrics. 2001;  32(4) 211-213
• 78 Etheridge L J, Beverley D W, Ferrie C, McManus E. The use of interferon beta in relapsing-remitting multiple sclerosis.  Arch Dis Child. 2004;  89(8) 789-791
• 79 Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.  Neuropediatrics. 2003;  34(3) 120-126
• 80 Ghezzi A, Amato M P, Capobianco M et al.. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.  Mult Scler. 2005;  11(4) 420-424
• 81 Pohl D, Rostasy K, Gartner J, Hanefeld F. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a.  Neurology. 2005;  64 888-890
• 82 Tenembaum S N, Segura M J. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis.  Neurology. 2006;  67 511-513
• 83 Pakdaman H, Fallah A, Sahraian M A, Pakdaman R, Meysamie A. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.  Neuropediatrics. 2006;  37(4) 257-260
• 84 Smith D. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.  J Neurol Sci. 2004;  223(1) 73-79
• 85 Hauser S L, Dawson D M, Lehrich J R et al.. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.  N Engl J Med. 1983;  308(4) 173-180
• 86 Weiner H L, Mackin G A, Orav E J et al.. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.  Neurology. 1993;  43(5) 910-918
• 87 Weiner H L, Cohen J A. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.  Mult Scler. 2002;  8(2) 142-154
• 88 Berger T, Deisenhammer F. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.  N Engl J Med. 2005;  353(16) 1744-1746
• 89 Langer-Gould A, Atlas S W, Green A J, Bollen A W, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.  N Engl J Med. 2005;  353(4) 375-381
• 90 Caldwell P H, Murphy S B, Butow P N, Craig J C. Clinical trials in children.  Lancet. 2004;  364(9436) 803-811
• 91 Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis.  JAMA. 2004;  291(15) 1875-1879
• 92 Pohl D, Krone B, Rostasy K et al.. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis.  Neurology. 2006;  67(11) 2063-2065
• 93 Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis.  Epidemiology. 2000;  11(2) 220-224
• 94 Ascherio A, Munger K L, Lennette E T et al.. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.  JAMA. 2001;  286(24) 3083-3088
• 95 Trowsdale J. Multiple sclerosis: putting two and two together.  Nat Med. 2006;  12(10) 1119-1121
• 96 Correale J, Tenembaum S N. Myelin basic protein and myelin oligodendrocyte glycoprotein T-cell repertoire in childhood and juvenile multiple sclerosis.  Mult Scler. 2006;  12(4) 412-420
• 97 Lucchinetti C F, Kiers L, O'Duffy A et al.. Risk factors for developing multiple sclerosis after childhood optic neuritis.  Neurology. 1997;  49(5) 1413-1418
• 98 Miyazawa R, Ikeuchi Y, Tomomasa T, Ushiku H, Ogawa T, Morikawa A. Determinants of prognosis of acute transverse myelitis in children.  Pediatr Int. 2003;  45(5) 512-516
• 99 Dunne K, Hopkins I J, Shield L K. Acute transverse myelopathy in childhood.  Dev Med Child Neurol. 1986;  28(2) 198-204
• 100 Defresne P, Hollenberg H, Husson B et al.. Acute transverse myelitis in children: clinical course and prognostic factors.  J Child Neurol. 2003;  18(6) 401-406
• 101 Jeffery A R, Buncic J R. Pediatric Devic's neuromyelitis optica.  J Pediatr Ophthalmol Strabismus. 1996;  33(5) 223-229
• 102 Wingerchuk D M, Weinshenker B G. Neuromyelitis optica: clinical predictors of a relapsing course and survival.  Neurology. 2003;  60(5) 848-853
• 103 Ghezzi A, Deplano V, Faroni J et al.. Multiple sclerosis in childhood: clinical features of 149 cases.  Mult Scler. 1997;  3(1) 43-46